2024 Full Year Results
30 April 2025
Lyn Rees, Chief Executive Officer
CEO of Novacyt Group since 1 May 2024
6 years as CEO of Yourgene Health
Drove the acquisition of Elucigene Diagnostics and Coastal Genomics and the fundraising to underpin
Prior to joining Yourgene, was Group CEO at British Biocell International (now BBI Group) for over 9 years
Completed 7 acquisitions during his tenure at
BBI Group
Steve Gibson, Chief Financial OfficerJoined Novacyt in 2017
Group Finance Director since February 2020, CFO since January 2024
Over 10 years in financial management at a globally recognised blue-chip, technology company
Broad commercial and international experience, including IPO
CIMA qualified over 15 years
International molecular diagnostics company with a growing portfolio of clinical assays, instrumentation and research tools. With deep focus and expertise across reproductive health, precision medicine and infectious disease.
Clinical IVD assays & DNA size selection
Research qPCR kits
Human Health: Reproductive Health - Precision Medicine - Infectious Disease
Non-Human Applications: Veterinary & Animal Health - Food, Water & Agriculture - Plant Genomics
Locations:
Manchester, UK
Miami, USA
Singapore
Canada
Commercial presence in over 65 countries
Headquartered in Le Vésinet in FranceListed on the:
London Stock Exchange's AIM market ("NCYT")
Paris Stock Exchange Euronext Growth ("ALNOV")
Novacyt Group employs around 230 globally